• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [23156 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2010     Committee for New Health Technology Assessment (CNHTA) [FBN1 exon deletion test[MLPA]]
2005     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Fast-track colonic surgery: a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (visual impairment due to diabetic macular oedema) - Benefit assessment acc. to § 35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Faricimab (neovascular age-related macular degeneration) - Benefit assessment according to § 35a Social Code Book V]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fampridine - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2006     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Familial hypercholesterolemia: evaluation of genetic screening by DNA microarrays]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Falls prevention for the elderly]
2012     German Agency for Health Technology Assessment at the German Institute for Medical Documentation and Information (DAHTA DIMDI) [Falls prevention for the elderly]
2013     Institut national d'excellence en sante et en services sociaux (INESSS) [Falls in patients living in health care facilities (short- and long-term care)]
2010     The Netherlands Organisation for Health Research and Development (ZonMw) [Falling in line with the guidelines. Development and pilot testing of an implementation strategy to increase physiotherapists' adherence to evidence-based guidelines for patients with low back pain; a planned, systematic, and theory-based approach]
2020     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Fall-safe assist. Portable device for falls prevention]
2011     Health Council of the Netherlands Gezondheidsraad (GR) [Fair compensation. Consideration of a proposal to give live kidney donors priority for transplants]
2017     Andalusian Health Technology Assessment Area (AETSA) [Faecal microbiota transplant for recurrent clostridium difficile infection. Up-date]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Fact sheet: Screening for gestational diabetes - rapid report]
2008     Committee for New Health Technology Assessment (CNHTA) [Facioscapulohumeral muscular dystrophy, D4Z4 analysis, PFGE/Southern Blot]
2014     Institut national d'excellence en sante et en services sociaux (INESSS) [Facility planning and infection prevention: sanitary facilities in specialized care rooms and cubicles]
2009     Committee for New Health Technology Assessment (CNHTA) [F7 gene, mutation[sequencing]]
2009     Committee for New Health Technology Assessment (CNHTA) [F12 gene, mutation[sequencing]]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ezetimibe for the prevention of cardiovascular events - Rapid report]
2011     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Ezetimibe for hypercholesterolaemia]
2008     Committee for New Health Technology Assessment (CNHTA) [Eyeball brachytherapy]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating devices]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Eye controlled speech generating device]
2009     Committee for New Health Technology Assessment (CNHTA) [Extremely low temperature cool chamber]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa L. - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extract from Cannabis sativa (spasticity due to multiple sclerosis) - Benefit assessment according to §35a Social Code Book V (expiry of the decision)]
2021     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracranial stereotactic body radiotherapy in oligometastasis]
2004     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal shock-wave treatment in orthopedics and rehabilitation. Update]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extracorporeal shock wave therapy in musculoskeletal disorders]
2023     Austrian Institute for Health Technology Assessment (AIHTA) [Extracorporeal shock wave therapy for orthopaedic indications]
2012     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Extracorporeal shock wave therapy (ESWT) for the treatment of delayed union or non-union of fractures]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extracorporeal shock wave therapy (ESWT) for heel pain]
2009     Committee for New Health Technology Assessment (CNHTA) [Extracorporeal photopheresis]
2016     Institut national d'excellence en sante et en services sociaux (INESSS) [Extracorporeal photopheresis: main indications and implementation parameters]
2024     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal membrane oxygenation for out-of-hospital cardiac arrest]
2009     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Extracorporeal liver support of liver failure by means of Prometheus system]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Extracorporeal High-Intensity Focused Ultrasound (HIFU) in solid tumours]
2008     Basque Office for Health Technology Assessment (OSTEBA) [External review and validation of methodological instruments for the critical reading and summary of scientific evidence]
2007     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [External manual. Part 1]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [External evaluation of DACEHTA]
2010     Agence d'évaluation des technologies et des modes d'intervention en santé (AETMIS) [External evaluation of cancer care organization and delivery: review of experiences relevant to the cancer team evaluation and designation process in Québec]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Extent of hysterectomy for endometriosis and / or adenomyosis of the uterus - Evidence report for the S3 guideline on diagnosis and treatment of benign diseases of the uterus]
2012     Andalusian Health Technology Assessment Area (AETSA) [Extended neonatal screening for lysosomal diseases by mass spectrometry]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Extended adjuvant endocrine therapy in breast cancer]
2006     Andalusian Health Technology Assessment Area (AETSA) [Expulsion stage of delivery: comparison of upright versus lying down positions for childbirth, through maternal and foetal outcomes]
2016     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploratory examination of the need for revision of the DMP "coronary heart disease"]
2020     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Exploratory evaluation of the relevance, use, and impacts of teleconsultations]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Surgery for varices" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Decompression for carpal tunnel syndrome" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Conization of the cervix uteri" - Rapid report]
2009     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exploration of the topic "Cataract surgery" -Rapid report]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Expertise on endometriosis]
2020     National Committee for Technology Incorporation (CONITEC) [Expansion of the use of sirolimus for the treatment of adult patients with lymphangioleiomyomatosis]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Expanding thrombolysis in acute ischemic stroke: organizing effective and efficient daily care in The Netherlands]
2024     Basque Office for Health Technology Assessment (OSTEBA) [Exoskeletons for the functional recovery of walking ability in patients with central nervous system disorders such as multiple sclerosis, stroke, and traumatic spinal injury]
2009     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy in patients with peripheral arterial disease: the costs and effectiveness of physiotherapeutic supervision with or without therapy feedback versus a 'go home and walk' advice]
2008     The Netherlands Organisation for Health Research and Development (ZonMw) [Exercise therapy for patellofemoral pain syndrome: a randomised clinical trial in general practice and sports medicine]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Exercise therapy (Krankengymnastik / Heilgymnastik) in physical medicine]
2020     HTA South [Exercise test in the investigation of suspected chronic coronary syndrome: a comparison with imaging and other functional tests]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exenatide in diabetes mellitus type 2 - Rapid report]
2020     National Committee for Technology Incorporation (CONITEC) [Exclusion of rifampicin for chemoprophylaxis for contacts of patients with Hansen´s disease]
2015     Institute for Clinical Effectiveness and Health Policy (IECS) [Exantia® tissue bulking agent for the treatment of fecal incontinence]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Examination of the usability of the scientific use files of the ZfKD in the framework of the determination of the SHI target population]
2010     Basque Office for Health Technology Assessment (OSTEBA) [Examination of barriers and facilitators for the implementation of clinical practice guidelines: a Delphi study]
2012     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Examination and treatment of older people after a fall – a health technology assessment]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene autotemcel (transfusion-dependent β-thalassaemia) - Assessment according to §35a Social Code Book V]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (ß-thalassaemia in patients ≥ 12 years); assessment according to §35a Social Code Book V; search for disease registries]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Exagamglogene (sickle cell disease in patients ≥ 12 years); assessment according to §35a Social Code Book (SGB) V; search for disease registries]
2018     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (primary hypercholesterolaemia or mixed dyslipidaemia) - Benefit assessment according to §35a Social Code Book V (new scientific findings)]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab (hypercholesterolaemia) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evolocumab - Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia; adults and adolescents >= 12 years) – Benefit assessment according to §35a Social Code Book V]
2024     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evinacumab (homozygous familial hypercholesterolaemia, 5 to 11 years) – Benefit assessment according to §35a Social Code Book V]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for vascular access care]
2015     Basque Office for Health Technology Assessment (OSTEBA) [Evidence-based recommendations for fall prevention]
2007     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence-based patient information on chronic obstructive airway diseases - Asthma]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence search for the S3 guideline on advice for vitamin D substitution]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12H: Psychological consequences of abortion. Evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12G: Routine follow-up examination: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12F: Anti-D prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12E: Telemedical evaluation: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12D: Antibiotic prophylaxis: evidence report for the S3 guideline on abortion in the first trimester]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12C: Surgical abortion: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12B: Comparison of methods: evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report: V21-12A: Sonographic proof: Evidence report for the S3 guideline on abortion in the first trimester]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: tumour resection]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Triage tests in the context of dysphagia diagnostics]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Self-evaluation of swallowing behaviour]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Prophylactic percutaneous endoscopic gastrostomy tube]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on oropharyngeal dysphagia due to head and neck tumours – diagnosis and treatment: Intensity-modulated radiotherapy under consideration of swallowing function]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: xanthine oxidase inhibitors]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: treatment of comorbidities]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: test accuracy of various methods for diagnosing gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: lifestyle changes for gout]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: drug treatment of a gout attack]
2023     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on diagnosis and treatment of gout: allopurinol versus febuxostat]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Technical support systems]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structured information on the initial diagnosis]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Structural imaging]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Evidence report for the S3 guideline on dementia: Non-drug interventions for mild cognitive impairment and biomarker evidence]